Linezolid Therapy of Staphylococcus aureus Experimental Osteomyelitis
Authors:
- 1 December 2000
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (12) , 3438-3440
Abstract
The in vivo activity of linezolid or cefazolin against a clinical isolate of methicillin-susceptible Staphylococcus aureus (linezolid MIC, 2 μg/ml) was studied in a rat model of experimental osteomyelitis. Sixty rats with experimental S. aureus osteomyelitis were treated for 21 days with no antimicrobial, with 25 μg of linezolid per kg of body weight administered intraperitoneally twice or three times a day, or with 50 μg of cefazolin per kg administered intramuscularly three times a day. After treatment, the animals were sacrificed and the infected tibiae were processed for quantitative bacterial cultures. The results of treatment were expressed as log 10 CFU/gram of bone and analyzed by rank sum analysis. The results of linezolid treatment were not significantly different from those of untreated controls, while cefazolin treatment was significantly more active than no treatment or linezolid treatment.Keywords
This publication has 6 references indexed in Scilit:
- Use of Linezolid, an Oxazolidinone, in the Treatment of Multidrug-Resistant Gram-Positive Bacterial InfectionsClinical Infectious Diseases, 2000
- Methicillin-Resistant Staphylococcus aureus Infection in a Renal Allograft Recipient Treated Successfully with a Novel New Antimicrobial Agent (Linezolid): New Treatment Options for Infections Due to Resistant OrganismsClinical Infectious Diseases, 1999
- In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant staphylococcus aureus and penicillin-resistant streptococcus pneumoniaeDiagnostic Microbiology and Infectious Disease, 1999
- Rat Model of Bacterial Osteomyelitis of the Tibia1999
- Role of Rifampin for Treatment of Orthopedic Implant–Related Staphylococcal Infections A Randomized Controlled TrialJAMA, 1998
- In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infectionsAntimicrobial Agents and Chemotherapy, 1996